NASDAQ:MDGL - Madrigal Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$286.95 -1.77 (-0.61 %)
(As of 07/20/2018 10:42 AM ET)
Previous Close$291.01
Today's Range$286.95 - $291.01
52-Week Range$15.19 - $325.98
Volume1,004 shs
Average Volume166,760 shs
Market Capitalization$4.09 billion
P/E Ratio-112.96
Dividend YieldN/A
Beta1.65
Madrigal Pharmaceuticals logoMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MDGL
CUSIP87162T20
Phone484-380-9263

Debt

Debt-to-Equity RatioN/A
Current Ratio29.12
Quick Ratio29.12

Price-To-Earnings

Trailing P/E Ratio-112.96
Forward P/E Ratio-118.57
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$13.02 per share
Price / Book22.04

Profitability

EPS (Most Recent Fiscal Year)($2.54)
Net Income$-31,150,000.00
Net MarginsN/A
Return on Equity-26.52%
Return on Assets-24.88%

Miscellaneous

Employees8
Outstanding Shares14,250,000
Market Cap$4,089.96

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) posted its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.33. View Madrigal Pharmaceuticals' Earnings History.

What price target have analysts set for MDGL?

9 analysts have issued twelve-month price targets for Madrigal Pharmaceuticals' stock. Their predictions range from $281.00 to $400.00. On average, they anticipate Madrigal Pharmaceuticals' share price to reach $318.00 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price. View Analyst Ratings for Madrigal Pharmaceuticals.

What is the consensus analysts' recommendation for Madrigal Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Madrigal Pharmaceuticals' key competitors?

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the folowing people:
  • Dr. Paul A. Friedman, Chairman, Pres & CEO (Age 75)
  • Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 64)
  • Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 66)

Has Madrigal Pharmaceuticals been receiving favorable news coverage?

Press coverage about MDGL stock has trended somewhat positive on Friday, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a coverage optimism score of 0.05 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 43.41 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fred Alger Management Inc. (0.11%), Bank of Montreal Can (0.02%), McQueen Ball & Associates Inc. (0.01%), Xact Kapitalforvaltning AB (0.01%), Amalgamated Bank (0.01%) and FNY Investment Advisers LLC (0.00%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Marc R Schneebaum, Rebecca Taub and Richard S Levy. View Institutional Ownership Trends for Madrigal Pharmaceuticals.

Which institutional investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including McQueen Ball & Associates Inc.. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last year include Bay City Capital Llc, Marc R Schneebaum and Rebecca Taub. View Insider Buying and Selling for Madrigal Pharmaceuticals.

Which institutional investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Bank of Montreal Can, Xact Kapitalforvaltning AB, Amalgamated Bank and FNY Investment Advisers LLC. View Insider Buying and Selling for Madrigal Pharmaceuticals.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $288.01.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $4.09 billion. The biopharmaceutical company earns $-31,150,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Madrigal Pharmaceuticals employs 8 workers across the globe.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 484-380-9263 or via email at [email protected]


MarketBeat Community Rating for Madrigal Pharmaceuticals (NASDAQ MDGL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote "Outperform" if you believe MDGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.